Inclusion Criteria:

- Advanced, heavily pretreated refractory multiple myeloma (MM).

- Patient should have exhausted all available anti MM therapies.

- Age ≥18 years.

- ECOG (Eastern Cooperative Oncology Group)performance status ≤ 2.

- Life expectancy of more than 3 months.

- No concomitant use of anticoagulants or antiplatelets drugs such as aspirin, NSAIDs
(Nonsteroidal Antiinflammatory Drug), Clopidogrel, Unfractionated Heparin, Low
Molecular Weight Heparin (e.g. Enoxaparin), Fondaparinux, Dabigatran, Rivaroxaban,
Apixaban and Warfarin.

- No platelets diseases or allergy to anticoagulants.

- WBC (White Blood Cell) ≥2000/µL; Platelets ≥100,000/µL; Hb ≥ 8 g/dL.

- Total bilirubin ≤ 1.5 x upper limit of normal (ULN); AST (aspartate
aminotransferase)and ALT (alanine aminotransferase)≤ 3 x the ULN; serum creatinine ≤
1.5 x the ULN (Upper Limit of Normal).

- aPTT, TT, INR, fibrinogen, D-dimer within ULN.

- Disease free of prior malignancies for ≥ 3 years.

- No acute gastrointestinal bleeding or any major bleeding (e.g CNS) in the past 2
years or any significant bleeding history.

- No known central nervous system involvement by myeloma.

- Capacity of understanding the nature of the trial and giving written informed
consent.

- Unless a female patient is post-menopausal or surgically sterilized, must be willing
to use an acceptable method of birth control (hormonal contraceptive, intrauterine
device, barrier contraceptive with spermicide, or abstinence) for the duration of the
study.

- Male patient must agree to use an acceptable method for contraception (barrier
contraceptive or abstinence) for the duration of the study.

Exclusion Criteria:

- Pregnancy or lactation or unwillingness to use adequate method of birth control

- Ascertained or presumptive hypersensitivity to the active principle and/or
formulations ingredients.

- Active uncontrolled viral, bacterial, or fungal infection or history of HIV,
hepatitis B or C, or any infection requiring systemic antivirals or antimicrobials.

- Grade ≥ 2 toxicity due to previous anti-neoplastic therapy (except alopecia), and
Grade ≥ 3 peripheral motor or sensory neuropathy, in the 2 weeks before treatment
(CTCAE V4.0).

- Less than 2 weeks since most recent chemotherapy, or concurrent chemotherapy.

- Presence of cirrhosis or chronic hepatitis.

- Diagnosis of amyloidosis or diagnosis of plasma cell leukaemia.

- Presence of serious cardiac (congestive heart failure, angina pectoris, myocardial
infarction within one year prior to study entry, uncontrolled hypertension or
arrhythmia), neurological or psychiatric disorder.

- Presence of uncontrolled intercurrent illness or any condition which in the judgement
of the investigator would place the subject at undue risk or interfere with the
results of the study.